IRWD Stock Analysis: Buy, Sell, or Hold?
IRWD - Ironwood Pharmaceuticals, Inc. - Class A
$3.64
-0.12 (-3.19%)
▼
5d:
-11.86%
30d:
-17.46%
90d:
-16.89%
HOLD
MODERATE Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 09, 2026
Get Alerted When IRWD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: IRWD shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: IRWD shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$10.30
Based on 14.0% avg growth
INTRINSIC VALUE TODAY
$6.39
43.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 3.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: IRWD is currently trading at $3.64, which is considered oversold relative to its 30-day fair value range of $3.99 to $4.36. From a valuation perspective, the stock is trading at a discount (Forward PE: 2.4) compared to its historical average (3.6). Remarkably, the market is currently pricing in an annual earnings decline of 12.6% over the next few years. This pessimistic expectation contrasts with the company's recent 125.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, IRWD is in a strong uptrend. The price is currently testing key support at $3.58. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: The stock scores a mixed 42/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.10 (+67.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, IRWD is in a strong uptrend. The price is currently testing key support at $3.58. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: The stock scores a mixed 42/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.10 (+67.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.99 -
$4.36
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (42/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.2%)
- BULLISH: Trading 67.6% below Wall St target ($6.10)
- NEUTRAL: Bottoming setup forming (42/100) — watch for confirmation
- CAUTION: 5-day price weakness (-11.9%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$3.99 -
$4.36
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.58
Resistance Level
$4.60
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
2.43
Wall Street Target
$6.10
(+67.6%)
Revenue Growth (YoY)
32.6%
Earnings Growth (YoY)
125.7%
Profit Margin
33.4%
Valuation Discount vs History
-12.6% cheaper
PE vs Historical
2.4 vs 3.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-12.6%
(market-implied from PE analysis)
1-Year Target
$3.28
(-10%)
2-Year Target
$2.95
(-19%)
3-Year Target
$2.65
(-27%)
3-Yr Target (if PE normalizes)
(PE: 2→4)
$3.94
(+8%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 24.0%)
$58.30
(+1502%)
Base:
(SPY PE: 2.4, Growth: 24.0%)
$6.93
(+91%)
Bear:
(PE: 2.1, Growth: 24.0%)
$5.89
(+62%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (5x PE), but valuation improves significantly next year (2x PE) as earnings recover.
Trailing PE: 5.01 | Current EPS (TTM): $0.75
Bull Case
$8.27
(+127%)
Analyst growth 100.0%, PE expands to 5.5
Base Case
$7.52
(+107%)
Market implied 100.0%, PE stable at 5.0
Bear Case
$2.56
(-30%)
Severe decline -20.0%, PE contracts to 4.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 2.4 to 3.6
Stabilization Target:
$5.40
(+48.4%)
PE Expansion Potential:
+48.4%
Share & Embed Analysis
Last updated: October 03, 2026 10:37 PM ET
Data refreshes hourly during market hours. Next update: 11:37 PM
Data refreshes hourly during market hours. Next update: 11:37 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IRWD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 47 HOLD |
